| Primary |
| Alpha-1 Anti-trypsin Deficiency |
90.6% |
| Product Used For Unknown Indication |
3.8% |
| Alpha-1 Anti-trypsin |
0.6% |
| Atrial Fibrillation |
0.6% |
| Cardiac Failure Congestive |
0.6% |
| Drug Therapy |
0.6% |
| Emphysema |
0.6% |
| Heart Rate Increased |
0.6% |
| Intravenous Catheter Management |
0.6% |
| Panniculitis |
0.6% |
| Respiratory Disorder |
0.6% |
|
| Pyrexia |
8.6% |
| Dyspnoea |
7.1% |
| Infusion Related Reaction |
7.1% |
| Arthralgia |
5.7% |
| Diarrhoea |
5.7% |
| Headache |
5.7% |
| Hypersensitivity |
5.7% |
| Urticaria |
5.7% |
| Anxiety |
4.3% |
| Dizziness |
4.3% |
| Infusion Site Extravasation |
4.3% |
| Muscle Spasms |
4.3% |
| Pneumonia |
4.3% |
| Rash |
4.3% |
| Rash Pruritic |
4.3% |
| Tremor |
4.3% |
| Urine Odour Abnormal |
4.3% |
| Vomiting |
4.3% |
| Blood Pressure Increased |
2.9% |
| Drug Effect Decreased |
2.9% |
|
| Secondary |
| Alpha-1 Anti-trypsin Deficiency |
90.7% |
| Atrial Fibrillation |
2.3% |
| Cardiac Assistance Device User |
2.3% |
| Primary Immunodeficiency Syndrome |
2.3% |
| Product Used For Unknown Indication |
2.3% |
|
| Alpha-1 Anti-trypsin Deficiency |
20.0% |
| Headache |
10.0% |
| Urticaria |
10.0% |
| Diarrhoea |
6.7% |
| Dyspnoea |
6.7% |
| Fatigue |
6.7% |
| Blood Pressure Decreased |
3.3% |
| Drug Interaction |
3.3% |
| Head Discomfort |
3.3% |
| Infusion Related Reaction |
3.3% |
| Infusion Site Extravasation |
3.3% |
| Migraine |
3.3% |
| Mycobacterial Infection |
3.3% |
| Product Formulation Issue |
3.3% |
| Product Taste Abnormal |
3.3% |
| Pruritus |
3.3% |
| Thrombosis |
3.3% |
| Vomiting |
3.3% |
|
| Concomitant |
| Chronic Obstructive Pulmonary Disease |
24.0% |
| Dyspnoea |
8.0% |
| Gastrooesophageal Reflux Disease |
8.0% |
| Glaucoma |
8.0% |
| Supplementation Therapy |
8.0% |
| Alpha-1 Anti-trypsin Deficiency |
6.0% |
| Convulsion |
6.0% |
| Alpha-1 Anti-trypsin Decreased |
4.0% |
| Blood Cholesterol Increased |
4.0% |
| Depression |
4.0% |
| Dysuria |
4.0% |
| Epilepsy |
4.0% |
| Herpes Simplex |
4.0% |
| Hypertension |
4.0% |
| Osteoporosis |
4.0% |
|
| Dry Mouth |
40.0% |
| Dyspnoea |
40.0% |
| Pharyngeal Oedema |
20.0% |
|
